Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, revumenib (SNDX-5613), and axatilimab (SNDX-6352). Co. is developing SNDX-5613, a small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia, and acute myeloid leukemia, or AML, and NPM1 mutant AML. Co. is also developing SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1, in chronic graft-versus-host disease, as well as idiopathic pulmonary fibrosis. The SNDX average annual return since 2016 is shown above.
The Average Annual Return on the SNDX average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SNDX average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SNDX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free SNDX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
